Unknown OBSERVATIONAL NCT05145101

Pneumococcal Vaccination in Patients With Chronic Lymphocytic Leukaemia (Pneumo-CLL)

Immunogenicity of the Currently Recommended Pneumococcal Vaccination Schedule in Patients With Chronic Lymphocytic Leukaemia.

Sponsor: Hannah Garcia Garrido

Conditions Chronic Lymphocytic Leukemia Invasive Pneumococcal Disease, Recurrent Isolated Pneumococcal Infections Vaccine-Preventable Diseases

Interventions Prevnar13

Updated 4 times since 2022 Last updated: Dec 3, 2021 Started: May 7, 2020 Primary completion: Mar 31, 2022 Completion: Mar 31, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05145101, this observational or N/A phase trial focuses on Chronic Lymphocytic Leukemia and Invasive Pneumococcal Disease, Recurrent Isolated and remains ongoing. Sponsored by Hannah Garcia Garrido, it has been updated 4 times since 2020, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown
Jul 2024 — Sep 2024 [monthly]

Unknown

Status: Unknown Status → Unknown
Jan 2024 — Jul 2024 [monthly]

Unknown Status

Status: Recruiting → Unknown Status
Jan 2022 — Jan 2024 [monthly]

Recruiting

First recorded

May 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hannah Garcia Garrido

Data source: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Amsterdam-Zuidoost, Netherlands